The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
|Articles|January 3, 2008
Massachusetts college receives $2 million donation from alumnus
Pharmacist donates $2 million to Massachusetts College of Pharmacy and Health Sciences
Advertisement
Richard E. Griffin, of Bedford, N.H., has donated $2 million to Massachusetts College of Pharmacy and Health Sciences to benefit its annual giving and capital campaign programs. Griffin is a 1971 graduate of the college and a member of the Board of Trustees.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
Pharmacist and public health expert Jennifer Hammons, PharmD, DrPH, discusses pharmacy as essential infrastructure amid rural pharmacies persistently being overlooked.
An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.
In an exploration of 2 distinct timeframes in the 21st century, researchers examine the use and concurrent use of medication types among elderly US adults.
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
Early CGMs Results in Better 5-Year Glucose Control in Type 1 Diabetes
3
Polypharmacy, Drug Interactions Threaten Older Adults’ Medication Safety
4
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
5